The first steps of leucine utilization are reversible deamination to α-ketoisocaproic acid (α-KIC) and irreversible oxidation. Recently the regulatory role of leucine deamination over oxidation was underlined in rodents. Our aim was to measure leucine deamination and reamination in the whole-body, in respect to previously determined rates across individual organs, in humans. By leucine and KIC isotope kinetics, we determined whole-body leucine deamination and reamination, and we compared these rates to those already reported across the sampled organs. As an in vivo counterpart of the "metabolon" concept, we analysed ratios between oxidation to either deamination or reamination. Leucine deamination to KIC was greater than KIC reamination to leucine in the whole-body (p=0.005), muscle (p=0.005) and the splanchnic area (p=0.025). These rates were not significantly different in the kidneys.
and organ leucine transamination and oxidation in humans. proposed a model of leucine deamination and reamination at whole body level, while Cheng et al. (1985) reported estimates of these rates across the human forearm. More recently, we reported the rates of leucine deamination, reamination and oxidation across the leg, the splanchnic area and the kidney (Tessari 1996) . However, in that study, we didn't report some additional data, which were not analyzed at that time yet, on whole body leucine deamination and reamination, to which organ rates could be compared.
This study aims to complete the picture of leucine deamination, reamination and oxidation rates across three major organs in humans, in comparison to the corresponding ones determined at whole body level. In addition, this study reports on a new model to measure whole-body leucine deamination, based on the infusion of an independent KIC tracer, conceptually similar to that previously used to estimate first pass splanchnic leucine uptake and deamination (Biolo 1997) . The contributions of skeletal muscle, the splanchnic bed and the kidneys, to whole body leucine deamination, reamination and oxidation, are also presented in the light of the "metabolon" concept, based on a combined analysis of leucine transamination and oxidation.
Material and methods
Subjects were enrolled between September 1993 and July 1994. The subjects' clinical characteristics, the inclusion criteria and the experimental design, had been previously reported (Tessari 1996) , except for an additional subject (male gender, age 56 yrs, BMI 25.8 kg/m 2 ), whose data became available after the publication of the original manuscript (Tessari 1996) . In addition to the previously reported tracers, all subjects had also been infused with the Sample processing and analytical methods were performed as described by Tessari et al. (1996) and Schwenk et al. (1984) . We employed a compartmental model in the analysis of the regional leucine metabolic steps, as previously reported (Tessari 1996 (see: Supplemental Methods and Supplemental Figure 1 ). Arterial and venous concentrations and enrichments (Supplemental Figure 2) of Leucine, Kic and CO 2 remained stable,
indicating that tracers and tracees were at steady state throughout the study.
Statistical analysis
The data were reported as Means ± SE. Organ as well as whole body kinetics data were normalized per 1.73 m 2 of body surface (Tessari 1996) . The Wilcoxon test for paired data was used to compare the rates of leucine deamination and reamination within each organ as well as in the whole body, using the Statistical Software (Version 7.1, StatSoft Italia). In addition, the data were analyzed also using the two tailed Student's t test for paired data. To compare the percent contribution of each organ to whole-body deamination or reamination rates, as well as the fraction of leucine oxidation over either leucine deamination to KIC or KIC reamination to leucine among the different organs, we employed the One Way ANOVA followed by the Newman Keuls post hoc test. A p value less than 0.05 was considered statistically significant.
The rates of whole-body leucine deamination to KIC were quite similar using either Model 1 as reported by Matthews (1981) or Model 2 (based on the data calculated from the infusion of the independent KIC tracer ( Figure 1 ).
Leucine deamination to KIC was greater than KIC reamination to leucine at whole body level (p=0.005), in skeletal muscle (p=0.005) and in the splanchnic area (p=0.025), whereas these rates were not significantly different from each other in the kidneys ( Figure   2A ), as previously reported (Tessari 1996) .
When expressed as percentage of whole-body rates, total skeletal muscle accounted for ≈60% of leucine deamination and ≈78% of leucine reamination, the splanchnic bed for ≈15% and ≈15%, and the kidneys for ≈12% and ≈18%, respectively ( Figure 2B ). The sum of the percent contributions by the three organs, to body leucine deamination to KIC was ≈87%, while that of KIC reamination to leucine was ≈112%.
Leucine flux through oxidation, deamination and reamination.
The sum of leucine deamination (the F7 model parameter) and leucine oxidation (F9), as well as the sum of reamination (F8) and oxidation, expressed both as µmoles/min and as percentage of whole body rates, are reported in Table 2 . In absolute terms, skeletal muscle accounted for the largest portion of these rates in respect to those of the whole-body, about 4-fold greater than those of either the splanchnic bed or the kidneys. In relative terms, the sum of the three sampled districts accounted for ≈80% (for F7+F8), and for 93% (for F8+F9), of the corresponding whole-body rates.
The ratios of leucine oxidation (F9) to deamination (F7), and that of leucine oxidation to reamination (F8), are reported in Figure 3 . These ratios indicate the fraction of leucine irreversible loss (through oxidation), over either leucine deamination to KIC ( Figure 3A ), or KIC reamination to leucine ( Figure 3B ), and they can approximate the "metabolon" concept (Tessari 1996) . Of note, the high rates of leucine deamination and reamination in muscle can provide nitrogen (N) for the synthesis of non-essential amino acids such as alanine and glutamine, the key nitrogen carriers from the periphery (skeletal muscle) to the liver.
We observed that in the whole body leucine deamination is 6-to 7-fold faster than oxidation (Tessari 1996), a finding similar to what was previously observed for valine also (Staten 1984) . A similar leucine deamination/oxidation ratio is observed in skeletal muscle and in splanchnic organs. These data suggest that in muscle and splanchnic organs the transamination step may regulate the free levels of the individual BCAA's, while decarboxylation limits their catabolism. Contrarywise, the leucine deamination and oxidation rates are similar in the kidney.
A new finding of this study is that the contribution by visceral organs to whole body leucine deamination and reamination rates is substantial (about one third of total), and almost equally shared by kidneys and splanchnic organs. In the fetal kidney BCAA transport is necessary for early nutrition and development (Guetg, 2015) .The adult kidney, in particular in the medullary thick ascending limb, is rich in all the enzymatic machinery involved in leucine catabolism and/or oxidation. Oxidation of leucine in this nephron segment may provide energy to sustain active ion transport (Tring-Trang-Tan, 1988 ).
The liver is thought to be the primary site for the oxidation of branched-chain keto acid (BCKA) but not BCAA (Brosnan & Brosnan, 2006) . In this study the contribution of splanchnic organs to whole body leucine deamination and reamination rate was greater than expected (~15%). However, we could not evaluate the oxidation of KIC to beta-hydroxybeta-methylbutyrate (HMB) by the enzyme KIC dioxygenase, a reaction which takes predominantly in the liver. In liver rats it has been observed that a minor percentage(about D r a f t 9 5%) of daily leucine metabolism is channeled through the dioxygenase pathway (Van Koevering and Nissen 1992).
Sites other than muscle and visceral organs, such as adipose tissue, brain, heart and lung (that couldn't be sampled in our study), should contribute minimally to leucine metabolism . However, concerning body fat, it should be considered that the data derived from skeletal muscle (i.e. leg) catheterization also include the contributions of both intramuscular and subcutaneous adipose tissue (Frick 1988).
One original contribution of our study is the investigation of the relative roles of leucine deamination, reamination and oxidation, both in the whole body and in selected organs in humans. By such data presentation, we intended to depict a sort of leucine "metabolon" in humans. Nevertheless, we are fully aware that the transfer of the "metabolon"
concept into the in vivo human setting is rather complex, and perhaps not entirely appropriate.
One example and/or limitation of such a transfer is given by the precursor substrate(s) of renal leucine oxidation. Since in the kidneys leucine deamination and reamination rates were not statistically different from each other leucine oxidation in the kidneys (≈4.5 µmol/min, unreported data) should have predominantly derived from other, unaccounted sources: one would likely be KIC itself. Indeed, as reported previously (Garibotto 2002), there was a net KIC uptake by the kidneys, of ≈3.3 µmol/min (using plasma data), a figure that, added to the net (albeit insignificant) difference between deamination and reamination (≈0.5 µmol/min), yields a total of 3.8 µmol/min, that would account for ≈85% of renal total leucine oxidation.
Therefore, should leucine oxidation in the kidneys predominantly derive from the KIC taken up (i.e. not from leucine deamination itself), thus directly entering the mitochondria for oxidation, this other oxidation route may not be strictly considered under the "metabolon"
concept. On the other hand, the limitation of our model and/or approach is intrinsically linked to the complexity of the studies in humans.
D r a f t
Another feature of BCAAs is the role of leucine as an anabolic nutrient signal to stimulate protein synthesis by activation of mTORC1, an effect reinforced by physical exercise and protein feeding. Several conditions causing wasting, such as sarcopenia of aging and inflammation blunt the leucine-induced mTORC1 1 activation (Ham, 2014) . A limitation of our study is that we evaluated leucine deamination only in the postabsorptive, basal state .
In addition, our patients were studied at rest, and the effects of physical exercise on leucine metabolism have not therefore been addressed. Further studies are required to understand mechanism and mediators which regulate deamination and reamination rates in sepsis. During sepsis, accelerated protein degradation is associated with increased transamination and oxidation of amino acids in skeletal muscle (Woolf 1979) . Reamination of KIC to leucine has also been shown to be enhanced in the liver of starved and endotoxin treated rats (Holecek 2001).
BCAA deamination and transamination is also a potential major topic in patients with Tessari, P., Garibotto, G., Inchiostro, S., Robaudo, C., Saffioti, S., Vettore, M., Zanetti, M., Russo, Figure 1 . Rates of whole body leucine deamination to KIC (i.e. of the KIC derived from leucine) calculated using either Model 1 (from Matthews 1993] or from Model 2 (Equations 4 to 6 of the compartmental model).
Data are Means ± SE of 10 subjects. The deamination data calculated with the two models were virtually identical (p>0.85 by paired t-test). and of KIC reamination to leucine (KIC→Leu), across total Skeletal Muscle (n=10), the Splanchnic Bed (n=8) and the Kidneys (n=7), as well as the Sum of the percentages of the three organs. The reported levels of statistical significance indicate the differences (by the One Way ANOVA and the Newman Keuls post hoc test) between rates in either the Splanchnic Bed or the Kidneys, and the corresponding ones in Skeletal Muscle. The Sum of rates from the three organs are reported as gross means (i.e. without SE), because not all subjects were studied across all the three organs. The sum of either deamination or reamination are not significantly different from 100% (p>0.7). Data are shown as Means ± SE. C-bicarbonate, which is required for the calculation of organ leucine oxidation, to be related to whole body rates. While our approach might have led to a possible, yet undetermined, recycling of 15 N-labeled amino groups from glutamate back to KIC to yield 15 Nleucine, such a potential bias would have been equally offset by a similar conceptual approach at organ level (Tessari 1996) .
In the following table, we show the data of whole-body leucine kinetics as measured in the present and those derived from the referenced (Matthews 1981) study. As it can be seen, our approach results in similar rates of leucine-carbon Ra, a ≈10% greater leucine-nitrogen Ra, similar oxidation rates, a ≈35% lower leucine deamination to KIC, and a ≈39% lower KIC reamination to leucine. Whether the observed differences are due to
Where : KIC Ra ven and KIC Ra art are the rates of appearance of KIC as measured using either vemous or arterial plasma 14 C-KIC SA.
Then:
Eq. 9: Deamination = Net transamination + Reamination A detailed description of these calculation is reported elsewhere (Tessari 1996) .
In the light of the recently proposed "Metabolon" concept, we also calculated the sum of leucine oxidation (F9) and either leucine deamination (F7) and KIC reamination (F8), across each organ as well as in the whole body. We used the whole body deamination data obtained with our model (see Eqs. 4 to 6), whereas for the reamination data we used Matthews's model (Matthews 1981) . These data are presented in Table 1 . In addition, we expressed organ leucine oxidation also a percent value of either deamination (F7) or reamination (F8) (Figure 3 ). However, since in one subject the deamination rate (F7) in the kidney was (slightly) negative, whereas in another the reamination rate (F8) in the splanchnic bed was (slightly) negative, the calculation of ratios of F9 over either F7 or F8 would yield large negative numbers. For this reason, we did not utilize these data for the calculations of the means. The organ data have been normalized per 1.73 m2 of body surface (Tessari 1996) . All data were expressed as µmol/min, either in the whole body or at each organ level. They are shown as Means±SE. 1981) . These potential, subtle differences in 15 N-leucine recycling using different tracers, possibly combined also with a somewhat larger analytical variation using both stable and radioactive isotope measurements in our study, vs. the use of only stable isotope analyses (Matthews 1981), might explain the above outlined limitation.
D r a f t
The second point concerns a possible, untoward effect derived from the combination of the 15 N isotope recycling with the specific site of isotope measurements (i.e. either plasma or whole-blood). Using plasma measurements (as we did in this study) Matthews's model (also developed on plasma measurements) (Matthews 1981) could be employed to our experimental conditions too, as anticipated above, and the resulting leucine deamination rate came out to be virtually identical to that determined with the simultaneous infusion of an independent KIC tracer, despite the use of different leucine tracers. We don't have a clear explanation for such a consistent and perhaps lucky result using plasma measurements. It is possible that whole-blood measurements (which required whole-blood deproteinization and had a somehow greater analytical variability), combined to possible specific effect due to the leucine isotopes employed, limited the feasibility of the use of whole-blood data in our experimental conditions.
In addition, a specific role of red blood cells in leucine handling (both labelled and unlabelled) cannot be excluded ( 
